SelectQuote, Inc. (SLQT)

SelectQuote (NYSE: SLQT) management highlighted what it described as a "strong quarter" driven by solid execution during the Medicare Advantage annual enrollment period (AEP), continued growth in its Healthcare Services segment, and recently announced financing and pharmacy benefit manager (PBM) agreements that the company said improve visibility and capital flexibility. At the same time, executives reduced

The heavy selling pressure might have exhausted for SelectQuote (SLQT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

SelectQuote, Inc. (SLQT) Q2 2026 Earnings Call Transcript

OVERLAND PARK, Kan.--(BUSINESS WIRE)--SelectQuote, Inc. (NYSE: SLQT) reported consolidated revenue for the second quarter of fiscal year 2026 of $537.1 million compared to consolidated revenue for the second quarter of fiscal year 2025 of $481.1 million. Consolidated net income for the second quarter of fiscal year 2026 was $69.3 million compared to consolidated net income for the second quarter of fiscal year 2025 of $53.2 million. Finally, consolidated Adjusted EBITDA* for the second quarter.

SelectQuote is downgraded to sell as Medicare Advantage reimbursement shocks threaten its core business model. SLQT's fundamentals are deteriorating, with Senior segment profitability slipping and commission revenue at risk from insurer belt-tightening. The 2027 Medicare reimbursement rate increase of just 0.09% is far below expectations, likely pressuring insurer and broker margins.

OVERLAND PARK, Kan.--(BUSINESS WIRE)--SelectQuote, Inc. (NYSE: SLQT), a leading distributor of Medicare insurance policies and owner of a rapidly growing Healthcare Services platform, today announced it will release its fiscal second quarter 2026 financial results before market open on Thursday, February 5, 2026. Chief Executive Officer, Tim Danker, and Chief Financial Officer, Ryan Clement, will host a conference call on the day of the release (February 5, 2026) at 8:00 am ET to discuss the re.

OVERLAND PARK, Kan.--(BUSINESS WIRE)--SelectQuote, Inc. (NYSE: SLQT) (the “Company”), a leading distributor of Medicare insurance policies and owner of a rapidly-growing healthcare services platform, today announced that its SelectRx pharmacy recently reached a new, multiyear agreement with a significant, long-time PBM (pharmacy benefit manager) partner. The new strategic agreement bolsters financial consistency and stability across both organizations. This agreement, which took effect on Janua.

BOSTON, Jan. 13, 2026 /PRNewswire/ -- Pathlight Capital LP ("Pathlight" or "Pathlight Capital") today announced that it is serving as the Administrative Agent on a $415 million senior secured credit facility for SelectQuote, Inc. ("SelectQuote," "SLQT" or the "Company"), a distributor of Medicare insurance policies and owner of a rapidly-growing healthcare services platform. As part of the facility, Pathlight underwrote and provided a $325 million term loan.

OVERLAND PARK, Kan.--(BUSINESS WIRE)--SelectQuote, Inc. (NYSE: SLQT) (the “Company”), a leading distributor of Medicare insurance policies and owner of a rapidly-growing healthcare services platform, today announced the successful completion of a new $415 million credit facility comprised of a $325 million term loan facility with Pathlight Capital LP (“Pathlight”) and an enhanced $90 million revolving credit facility with UMB Bank (“UMB”). The new credit facility immediately strengthens the com.

James River Group (NASDAQ: JRVR - Get Free Report) and SelectQuote (NYSE: SLQT - Get Free Report) are both small-cap finance companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, profitability and valuation. Volatility and Risk James River Group has

Yuanbao (NASDAQ: YB - Get Free Report) and SelectQuote (NYSE: SLQT - Get Free Report) are both small-cap finance companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, valuation, earnings, risk and dividends. Valuation and Earnings This table compares Yuanbao and SelectQuote"s

BOSTON, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Berman Tabacco, a national law firm representing investors, announces its investigation into potential stockholder claims involving SelectQuote, Inc. (“SelectQuote”) (NYSE:SLQT) allegedly receiving illegal payments from health insurance providers.

BOSTON, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Berman Tabacco, a national law firm representing investors, announces its investigation into potential stockholder claims involving SelectQuote, Inc. (“SelectQuote”) (NYSE:SLQT) allegedly receiving illegal payments from health insurance providers.

SelectQuote (NYSE: SLQT - Get Free Report) and Radian Group (NYSE: RDN - Get Free Report) are both finance companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings. Analyst Recommendations This is a summary of current ratings

BOSTON, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Berman Tabacco, a national law firm representing investors, announces its investigation into potential stockholder claims involving SelectQuote, Inc. (“SelectQuote”) (NYSE:SLQT) allegedly receiving illegal payments from health insurance providers.

SelectQuote faces mounting challenges, including weaker growth in its core SelectRx segment and heightened industry headwinds impacting policy sales and retention. SLQT's revenue mix is shifting toward recurring pharmacy benefits, but razor-thin margins and recent member losses raise concerns about long-term profitability. Despite trading at a low 5x EV/FY26 adjusted EBITDA, SLQT's high debt load and uncertain outlook make its valuation less compelling.